Patient cohort
A total of 186 charts of patients treated at the Hôpitaux Universitaires
de Genève (HUG) with rituximab met the following inclusion criteria of
newly diagnosed histologically proven aggressive B-cell lymphoma and
treated with at least two consecutive doses of fractionated rituximab 24
hours apart during the first cycle of treatment. Patients were excluded
if they had non-B-cell lymphoma histology, administration of a single
dose of rituximab, required chronic dialysis, were under 18-year old and
in the absence of written informed consent. The Ethics Committee of
Geneva (CCER 2020-01659) approved the study. Written informed consent
was obtained in accordance with the declaration of Helsinki from alive
patients (hospital general consent for clinical data use), and a waiver
was applied for deceased patients when obtaining consent was not
possible.